The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Heart failure is a global pandemic affecting an estimated 26 million people worldwide and resulting in more than 1 million hospitalizations annually in both the United States and Europe. Although the outcomes for ambulatory HF patients with a reduced ejection fraction (EF) have improved with the discovery of multiple evidence-based drug and device therapies, hospitalized heart failure (HHF) patients continue to experience unacceptably high post-discharge mortality and readmission rates that have not changed in the last 2 decades. In addition, the proportion of HHF patients classified as having a preserved EF continues to grow and may overtake HF with a reduced EF in the near future. However, the prognosis for HF with a preserved EF is similar and there are currently no available disease-modifying therapies. HHF registries have significantly improved our understanding of this clinical entity and remain an important source of data shaping both public policy and research efforts. The authors review global HHF registries to describe the patient characteristics, management, outcomes and their predictors, quality improvement initiatives, regional differences, and limitations of the available data. Moreover, based on the lessons learned, they also propose a roadmap for the design and conduct of future HHF registries.

[1]  G. Fonarow,et al.  Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2007, American heart journal.

[2]  K. Swedberg,et al.  Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. , 2013, Journal of the American College of Cardiology.

[3]  Y. Sakata,et al.  Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[4]  M. Gheorghiade,et al.  The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. , 2011, American heart journal.

[5]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[6]  E. Braunwald,et al.  Hospitalizations for heart failure in the United States--a sign of hope. , 2011, JAMA.

[7]  C. O'connor,et al.  Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. , 2004, American heart journal.

[8]  M. Gheorghiade,et al.  Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction , 2011, Evidence Based Medicine.

[9]  François Alla,et al.  Heart failure burden and therapy. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  P. Ponikowski,et al.  EURObservational Research Programme: The Heart Failure Pilot Survey (ESC‐HF Pilot) , 2010, European journal of heart failure.

[11]  D. Grobbee,et al.  Angiotensin converting enzyme inhibition and hospitalisation rates for heart [letter] , 2002 .

[12]  M. Gheorghiade,et al.  The potential application of electrophysiology diagnostics and therapeutics in acute heart failure syndromes , 2011, Heart Failure Reviews.

[13]  I. Piña,et al.  Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.

[14]  C. Phillips,et al.  Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. , 2008, The American journal of cardiology.

[15]  M. Gheorghiade,et al.  Strategies and opportunities for drug development in heart failure. , 2013, JAMA.

[16]  C. O'connor,et al.  Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). , 2008, The American journal of cardiology.

[17]  C. O'connor,et al.  Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, American heart journal.

[18]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[19]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[20]  Perry M. Elliott,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[21]  P. Ponikowski,et al.  Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.

[22]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[23]  M. Cheitlin Influence of Beta-Blocker Continuation or Withdrawal on Outcomes in Patients Hospitalized With Heart Failure: Findings From the OPTIMIZE-HF Program , 2009 .

[24]  G. Fonarow,et al.  Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE‐HF , 2012, European journal of heart failure.

[25]  William T. Abraham,et al.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness , 2005 .

[26]  C. Phillips,et al.  Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[27]  K. Swedberg,et al.  Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. , 2008, JAMA.

[28]  Sanjiv J Shah,et al.  Heart failure with preserved ejection fraction: treat now by treating comorbidities. , 2008, JAMA.

[29]  V. Hasselblad,et al.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.

[30]  C. O'connor,et al.  Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. , 2010, American heart journal.

[31]  G. Fonarow,et al.  Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2006, Journal of cardiac failure.

[32]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[33]  C. O'connor,et al.  Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). , 2007, Archives of internal medicine.

[34]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[35]  W. Frishman,et al.  Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure , 2007 .

[36]  Monica R. Shah,et al.  Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness The ESCAPE Trial , 2005 .

[37]  J. McMurray,et al.  Trends in hospitalization for heart failure in Scotland, 1990-1996. An epidemic that has reached its peak? , 2001, European heart journal.

[38]  Christopher M O'Connor,et al.  Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. , 2010, Journal of the American College of Cardiology.

[39]  L. Tavazzi,et al.  Acute heart failure patient profiles, management and in‐hospital outcome: results of the Italian Registry on Heart Failure Outcome , 2012, European journal of heart failure.

[40]  G. Fonarow,et al.  Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2007, American heart journal.

[41]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[42]  L. Dušek,et al.  Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry , 2011, Critical care.

[43]  Wan Azman Wan Ahmad,et al.  Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). , 2012, Journal of cardiac failure.

[44]  Javed Butler,et al.  Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. , 2011, Journal of cardiac failure.

[45]  K. Swedberg,et al.  Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. , 2008, Journal of the American College of Cardiology.

[46]  G. Fonarow,et al.  Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZE‐HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) * , 2008, European journal of heart failure.

[47]  I. Piña,et al.  Heart failure in women: a need for prospective data. , 2009, Journal of the American College of Cardiology.

[48]  G. Boriani,et al.  A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[49]  C. O'connor,et al.  Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). , 2008, The American journal of cardiology.

[50]  M. Gheorghiade,et al.  Heart failure in 2010: One step forward, two steps back , 2011, Nature Reviews Cardiology.

[51]  Gerasimos Filippatos,et al.  Epidemiology of acute heart failure syndromes , 2007, Heart Failure Reviews.

[52]  C. O'connor,et al.  Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. , 2003, American heart journal.

[53]  Piotr Ponikowski,et al.  EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) , 2013, European journal of heart failure.

[54]  M. Drazner,et al.  Characteristics and outcomes in African American patients with decompensated heart failure. , 2008, Archives of internal medicine.

[55]  G. Fonarow,et al.  Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). , 2009, The American journal of cardiology.

[56]  V. Hasselblad,et al.  Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial). , 2004, The American journal of cardiology.

[57]  M. Gheorghiade,et al.  The potential role of cardiac resynchronization therapy in acute heart failure syndromes , 2011, Heart Failure Reviews.

[58]  J. Butler,et al.  Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. , 2003, Journal of the American College of Cardiology.

[59]  R. Wexler Early physician follow-up and 30-day readmission among older patients with heart failure. , 2010, JAMA.

[60]  G. Ogedegbe,et al.  Heart failure–associated hospitalizations in the United States. , 2013, Journal of the American College of Cardiology.

[61]  M. Vaduganathan,et al.  The disconnect between phase II and phase III trials of drugs for heart failure , 2013, Nature Reviews Cardiology.

[62]  Harlan M Krumholz,et al.  National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. , 2011, JAMA.

[63]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[64]  D. Grobbee,et al.  Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? , 2002, Heart.

[65]  L. Schwamm,et al.  Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failure. , 2009, American heart journal.

[66]  G. Fonarow,et al.  Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. , 2007, European heart journal.

[67]  A. Cohen-Solal,et al.  Clinical profile, contemporary management and one‐year mortality in patients with severe acute heart failure syndromes: The EFICA study ☆ , 2006, European journal of heart failure.

[68]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[69]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[70]  C. Yancy,et al.  Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. , 2010, JAMA.

[71]  R. Bonow,et al.  Postdischarge assessment after a heart failure hospitalization: the next step forward. , 2010, Circulation.

[72]  R. Porcher,et al.  Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF) , 2011, Intensive Care Medicine.

[73]  Kevin L. Thomas,et al.  Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. , 2011, American heart journal.

[74]  J. Piccini,et al.  Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions , 2011, Heart Failure Reviews.

[75]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[76]  G. Fonarow,et al.  Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. , 2008, Journal of the American College of Cardiology.

[77]  C. Yancy,et al.  Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). , 2007, American heart journal.

[78]  K. Adams,et al.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.

[79]  William T. Abraham,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree analysis , 2005 .

[80]  K. Swedberg,et al.  Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. , 2003, European Heart Journal.

[81]  Eliot Corday,et al.  Overview of Acutely Decompensated Congestive Heart Failure (ADHF): A Report from the ADHERE Registry , 2005, Heart Failure Reviews.

[82]  G. Filippatos,et al.  Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. , 2012, European heart journal.

[83]  Deepak L. Bhatt,et al.  Presence of Atrial Fibrillation Is Independently Associated With Adverse Outcomes in Patients Hospitalized With Heart Failure: An Analysis of Get With The Guidelines–Heart Failure , 2012, Circulation. Heart failure.

[84]  M. Vaduganathan,et al.  Thirty-day readmissions: the clock is ticking. , 2013, JAMA.

[85]  G. Fonarow,et al.  High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. , 2007, Journal of cardiac failure.

[86]  R. Bonow,et al.  Heart failure: Early follow-up after hospitalization for heart failure , 2010, Nature Reviews Cardiology.

[87]  D. J. Veldhuisen,et al.  Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions , 2014, Heart Failure Reviews.

[88]  G. Fonarow,et al.  Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, Journal of the American College of Cardiology.

[89]  Mark D. Huffman,et al.  Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[90]  Deepak L. Bhatt,et al.  Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. , 2012, American heart journal.

[91]  D. Mozaffarian,et al.  Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.